Germany's Boehringer Ingelheim logs fastest CAGR in diabetes drug segment

With a turnover of Rs 3.56 bn from the anti-diabetes segment, the firm enjoys a 3.18% share in the over Rs 100-bn Indian market

German pharma major Boehringer Ingelheim clocked a 43.7 per cent compounded annual growth rate (CAGR) in the domestic anti-diabetes therapy segment in the past three years, catapulting to the eighth spot from the 15th position in 2016. 

The company’s new launches and marketing tie-ups helped propel growth. 

Boehringer saw the highest growth among leading diabetes players in the market. With a turnover of Rs 3.56 billion from the anti-diabetes segment, the company enjoys a 3.18 per cent market share in the over Rs 100 billion Indian diabetes market. 

Boehringer Ingelheim India’s Managing Director Sharad Tyagi said the company had a